$OABI News

OmniAb (OABI) Q3 2026 Earnings Call Transcript

OmniAb Q3 Earnings Call Highlights

OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

OmniAb to Participate in Upcoming Investor Conferences in November

OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference

OmniAb to Report Third Quarter 2026 Financial Results on October 30

OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

OmniAb to Host Investor & Analyst Day on October 6, 2026

Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?

VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

OmniAb to Participate in Upcoming Investor Conferences

OmniAb lifts 2026 cash outlook following licensing momentum

OmniAb Raises 2026 Financial Guidance

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company